AR111494A1 - Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer - Google Patents
Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncerInfo
- Publication number
- AR111494A1 AR111494A1 ARP180101102A ARP180101102A AR111494A1 AR 111494 A1 AR111494 A1 AR 111494A1 AR P180101102 A ARP180101102 A AR P180101102A AR P180101102 A ARP180101102 A AR P180101102A AR 111494 A1 AR111494 A1 AR 111494A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- anilinoquinazoline
- compounds
- cancer treatment
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical compound N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052731 fluorine Chemical group 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El proceso para su preparación; las composiciones farmacéuticas que los contienen y su uso en el tratamiento de las enfermedades mediadas por KIT. Reivindicación 1: Un compuesto de la fórmula (1), o una sal del mismo aceptable desde el punto de vista farmacéutico, caracterizado porque: R¹ se selecciona de hidrógeno y flúor; R² se selecciona de flúor y alcoxi C₁₋₂; R³ se selecciona de hidrógeno y metoxi; y R⁴ es un alquilo C₁₋₃, opcionalmente sustituido con un grupo seleccionado de alcoxi C₁₋₃ y NR⁵R⁶, en donde R⁵ y R⁶ son cada uno independientemente hidrógeno o metilo; o un anillo de heterociclilo de 4 a 6 elementos que contiene un átomo de oxígeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490859P | 2017-04-27 | 2017-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111494A1 true AR111494A1 (es) | 2019-07-17 |
Family
ID=62091877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101102A AR111494A1 (es) | 2017-04-27 | 2018-04-27 | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10273227B2 (es) |
| EP (1) | EP3615522B1 (es) |
| JP (1) | JP7128204B2 (es) |
| KR (1) | KR102603153B1 (es) |
| CN (1) | CN110573505B (es) |
| AR (1) | AR111494A1 (es) |
| AU (1) | AU2018259078B2 (es) |
| CA (1) | CA3059283A1 (es) |
| ES (1) | ES2888298T3 (es) |
| MX (1) | MX389244B (es) |
| RU (1) | RU2769694C2 (es) |
| TW (1) | TWI774758B (es) |
| WO (1) | WO2018197642A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389244B (es) * | 2017-04-27 | 2025-03-20 | Astrazeneca Ab | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer |
| US20210380685A1 (en) * | 2018-10-18 | 2021-12-09 | Sinomab Bioscience Limited | Methods of Treating Rheumatoid Arthritis |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| EP4146175A1 (en) | 2020-05-08 | 2023-03-15 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| WO2022040341A1 (en) * | 2020-08-20 | 2022-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Abscopal therapy for cancer |
| KR20230066391A (ko) | 2020-09-10 | 2023-05-15 | 젠맵 에이/에스 | 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 |
| IL301102A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| MX2023002546A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpos biespecificos contra cumulo de diferenciacion 3 (cd3) y contra cumulo de diferenciacion 20 (cd20) para tratar leucemia linfocitica cronica. |
| MX2023002545A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes. |
| WO2022053655A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| MX2024007044A (es) * | 2021-12-09 | 2024-09-04 | Deciphera Pharmaceuticals Llc | Compuestos heterociclicos como inhibidores de kit quinasa. |
| WO2025188669A1 (en) * | 2024-03-04 | 2025-09-12 | Cardiff Oncology, Inc. | Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| PL354323A1 (en) * | 1999-09-21 | 2004-01-12 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
| DK1382604T3 (da) | 2001-04-27 | 2006-04-18 | Kirin Brewery | Quinolinderivater med en azolylgruppe og quinazolinderivater |
| TW200505452A (en) | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| US20050165031A1 (en) * | 2003-11-13 | 2005-07-28 | Ambit Biosciences Corporation | Urea derivatives as ABL modulators |
| CA2581516C (en) | 2004-10-12 | 2013-06-11 | Astrazeneca Ab | Quinazoline derivatives |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20070106549A1 (en) | 2005-11-04 | 2007-05-10 | Stocking Christine A | Turnkey aviation budget management |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
| WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| JP5699075B2 (ja) | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102532042A (zh) | 2010-12-30 | 2012-07-04 | 上海医药工业研究院 | 一种芳基脲类化合物、其中间体及其应用 |
| CN102918029B (zh) * | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| CN103254142B (zh) | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CN104130200B (zh) | 2014-07-01 | 2016-04-20 | 中山大学 | 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用 |
| US11053223B2 (en) | 2017-04-27 | 2021-07-06 | Astrazeneca Ab | Phenoxyquinazoline compounds and their use in treating cancer |
| MX389244B (es) * | 2017-04-27 | 2025-03-20 | Astrazeneca Ab | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer |
-
2018
- 2018-04-26 MX MX2019012847A patent/MX389244B/es unknown
- 2018-04-26 EP EP18721348.3A patent/EP3615522B1/en active Active
- 2018-04-26 TW TW107114297A patent/TWI774758B/zh active
- 2018-04-26 CN CN201880027620.0A patent/CN110573505B/zh active Active
- 2018-04-26 AU AU2018259078A patent/AU2018259078B2/en active Active
- 2018-04-26 ES ES18721348T patent/ES2888298T3/es active Active
- 2018-04-26 WO PCT/EP2018/060798 patent/WO2018197642A1/en not_active Ceased
- 2018-04-26 RU RU2019136279A patent/RU2769694C2/ru active
- 2018-04-26 KR KR1020197034070A patent/KR102603153B1/ko active Active
- 2018-04-26 JP JP2019557764A patent/JP7128204B2/ja active Active
- 2018-04-26 US US15/963,122 patent/US10273227B2/en active Active
- 2018-04-26 CA CA3059283A patent/CA3059283A1/en active Pending
- 2018-04-27 AR ARP180101102A patent/AR111494A1/es unknown
-
2019
- 2019-03-05 US US16/292,817 patent/US10829479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2888298T3 (es) | 2022-01-03 |
| US10829479B2 (en) | 2020-11-10 |
| CN110573505A (zh) | 2019-12-13 |
| TWI774758B (zh) | 2022-08-21 |
| KR102603153B1 (ko) | 2023-11-15 |
| TW201904960A (zh) | 2019-02-01 |
| RU2769694C2 (ru) | 2022-04-05 |
| CA3059283A1 (en) | 2018-11-01 |
| RU2019136279A (ru) | 2021-05-27 |
| CN110573505B (zh) | 2023-04-11 |
| KR20190141203A (ko) | 2019-12-23 |
| JP7128204B2 (ja) | 2022-08-30 |
| JP2020517677A (ja) | 2020-06-18 |
| US20180312490A1 (en) | 2018-11-01 |
| EP3615522A1 (en) | 2020-03-04 |
| AU2018259078A1 (en) | 2019-10-17 |
| EP3615522B1 (en) | 2021-08-04 |
| BR112019022229A2 (pt) | 2020-05-12 |
| MX389244B (es) | 2025-03-20 |
| US10273227B2 (en) | 2019-04-30 |
| WO2018197642A1 (en) | 2018-11-01 |
| AU2018259078B2 (en) | 2021-10-07 |
| US20190263787A1 (en) | 2019-08-29 |
| RU2019136279A3 (es) | 2021-05-31 |
| MX2019012847A (es) | 2022-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| AR114971A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR094784A1 (es) | Compuestos de tubulisina, métodos para obtenerlos y uso | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR097325A1 (es) | Pirroles anillados | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR104880A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
| AR099047A1 (es) | Derivados etinilo | |
| AR098723A1 (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
| AR123241A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |